Recently, ultrasound-targeting microbubble destruction has been employed in molecular gene therapy, and a new potent nonviral gene transfer method known as 'sonoporation' has been developed. We investigated the efficiency of sonoporation toward growth inhibition of human gingival squamous carcinoma cell line, Ca9-22, in vitro and in vivo. The cytotoxicity of bleomycin (BLM) was investigated using flow-cytometric analysis and Hoechst's staining in vitro assay systems. We found that the delivery of BLM by sonoporation induced cytotoxic effect toward Ca9-22 cells in vitro. Our in vivo results showed that tumors nearly disappeared in Ca9-22 cell-implanted nude KSN/slc mice treated with a low dose of BLM followed by sonoporation during the 4-week experimental period. Histological analysis revealed that the cytotoxic effect was mainly apoptosis. We previously reported that the cytolethal distending toxin B (cdtB) from Actinobacillus actinomycetemcomitans, a periodontopathic bacterium, is responsible for cell cycle arrest and apoptosis in vitro. Thus, we used sonoporation to transfect a cdtB-expressing plasmid into Ca9-22 cells and examined cell viability in vitro and in vivo. We found that an administration of cdtB-expressing plasmid followed by sonoporationinduced marked growth inhibition of Ca9-22 cells and apoptotic cells were also observed in vitro and in vivo. These findings suggest that local administration of cytotoxic agents with sonoporation is a useful method for molecular cancer therapy.
Introduction
The clinical usefulness of ultrasonication for diagnostic purpose in medicine has been reported and the method was recently proposed to provide promising physical stimuli to enhance the efficacy of therapeutic drugs and diagnostic agents in vivo. 1 Further, recent progress in molecular technology has led to dramatic developments in gene therapy for cancer. Although use of a viral vector for gene therapy leads to more efficient transfection, several studies have noted reservations regarding immune response and mutagenesis with viral infection. [2] [3] [4] However, Sakakima et al. 5 recently reported results showing that gene therapy with ultrasonication may become a new and safe treatment for hepatocellular cartinoma. Ultrasonication techniques have been used in vivo and in vitro to load antiproliferating agents, oligonucleotides, proteins and plasmid DNA into cells, as well as for an efficient nonviral approach, 1, 6, 7 whereas others have reported the efficiency of the 'sonoporation' method for gene therapy. 5 It is well known that bleomycin (BLM) acts as an enzyme when treating single-and double-strand DNAbreaks and functions as a hydrophilic and chargedcytotoxic agent. 8, 9 As BLM has been used as an agent for drug delivery by electroporation, we established a system of delivery of chemotherapeutic agents into human gingival squamous cell carcinoma tissue by focused sonoporation in the present study.
Exposure of mammalian cells to bacterial exotoxins evokes complicated cellular responses, such as a reversible block of the cell-cycle progression in the G1 and G2/M phases and induction of programed cell death. 10 Some studies have reported that cytolethal distending toxin A (cdtA), cdtB and cdtC, derived from pathogenic bacteria, inhibited the proliferation of several mammalian cells by inducing a block of the G2 phase of the cell cycle. 11 Among those three proteins, cdtB from C. jejuni exhibited features of type 1 deoxyribonucleases and was the main component of cell-growth arrest induction. 12 We previously cloned the cdtA, cdtB and cdtC genes of Actinobacillus actinomycetemcomitans, a periodontopathic bacterium, 13 using a constructed E. coli expression system and purified their gene products, cdtA, cdtB and cdtC. 14 Further, we recently established an in vitro system for delivery of recombinant cdtB (rcdtB) protein into gingival squamous cell carcinoma cells using a BioPOR-TER and found that the delivery of rcdtB from A. actinomycetemcomitans caused cell distension and G2-cell cycle arrest in a gingival squamous cell carcinoma cell line, Ca9-22. 15 The present study was undertaken to establish in vitro and in vivo systems of delivery of BLM using sonoporation. We also examined the effects of cdtB gene transfection with sonoporation on the viability of Ca9-22 cells in vitro. Finally, we explored the efficacy of in vivo transfection of a cdtB-expressing plasmid by focused sonoporation with Ca9-22 cells implanted into nude mice.
Materials and methods
Cell line, reagents, and plasmids Ca9-22, a human gingival squamous carcinoma cell line, was maintained in Dulbecco's Modified Eagle Medium (DMEM; GIBCO BRL, Grand Island, NY) with 10% heat-inactivated fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml). 16 Optison, a microbubble echo-contrast agent that contains about 5 to 8 Â 10 8 /ml of gas bodies between 2 and 4.5 mm in diameter filled with octa-perfluoropropane and stabilized by human-albumin shells, was obtained from Amersham Health Inc. (Princeton, NJ). BLM was purchased from LKT laboratories (St. Paul, MN). The cdtB gene of A. actinomycetemcomitans was prepared as described previously. 17 The cdtB gene was originally cut from pET-28a( þ ), ligated to pVIVO1-mcs (Invitrogen, San Diego, CA), and designated pVIVO1-cdtB. 15 The pEF1a-b-GAL expression plasmid was a kind gift from Dr. Takeyoshi Koseki (Tohoku University). 18 In vitro sonoporation Intracellular delivery of BLM and transfection of pVI-VO1-cdtB or b-galactosidase gene were performed by sonoporation with or without Optison. The cultured cells were trypsinized, washed twice in phosphate-buffered saline (PBS; pH 7.2) and resuspended at 1.5 Â 10 6 cells/ 600 ml of serum-free DMEM in a 48-well plate. BLM, pVIVO1-cdtB or the b-galactosidase gene was added to an Optison solution, then mixed and kept for 30 s, after which a BLM and Optison solution (600 ml; 1:50) or pVIVO1-cdtB and Optison solution (600 ml; 1:10) was added to the cell medium. The final concentrations of BLM and pVIVO1-cdtB were 5 mg/ml and 330 mg/ml, respectively. After the mixed solution was added to the wells, the cells were exposed to sonoporation for 20 s at room temperature using a ultrasonication transducer (Sonitron 2000, Rich Mar Inc, Inola, OK) at 1 MHz, with an output intensity of 1.0 W/cm 2 and a 10% duty cycle for the delivery of BML and at 1 MHz, with an output intensity of 2.0 W/cm 2 and a 10% duty cycle for the transfection of pVIVO1-cdtB or the b-galactosidase gene. For the latter, the head of the transducer was directly immersed into the cell suspension. The ultrasonication probe and well plate were firmly fixed to a stand to avoid dislocation during sonoporation exposure. Cell viability was determined by staining with trypan blue dye.
Detection of apoptotic cells and b-galactosidasepositive cells Ca9-22 cells were suspended in a hypotonic solution (0.1%. Triton X-100, 1 mM Tris-HCl (pH 8.0), 3.4 mM sodium citrate 0.1 mM ethylenediaminetetraacetic acid), stained with 5 mg/ml of propidium iodide and analyzed with a FACScalibur flow cytometer (EPICS XL; Beckman Coulter, Fullerton, CA). For Annexin V/PI staining, the cells were washed with PBS and resuspended in binding buffer (10 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 140 mM NaCl, 2.5 mM CaCl, pH 7.4). Fluorescein-conjugated Annexin V and PI solutions (Molecular Probe, Inc., Eugene, OR) were added to the cells and gently mixed, after which the cells were incubated at room temperature and analyzed using an EPOCS XL. To detect apoptotic nuclei, Ca9-22 cells were fixed with 1% glutaraldehyde for 1 h and washed with PBS. The samples were stained with 56 mg/ml of Hoechst dye 33342 and mounted on glass slides. Nuclei were visualized by fluorescence microscopy with an excitation wavelength of 355 nm and emission wavelength of 465 nm. In some experiments, the cells were fixed with 3% paraformaldehyde and stained with X-Gal (5-bromo-4-chloro-3-indolyl-b-d-galactoside) (WAKO, Osaka, Japan) in PBS containing 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 and MgCl 2 . Reactions were carried out at 371C for 24 h.
In vivo sonoporation
Male KSN/slc nude mice were purchased from SLC (Shizuoka, Japan) at 6-weeks-of age. A total of 16 mice were divided into four experimental groups of four animals each, which were the control (C), sonoporation (S), injection of BLM (B) and injection of BLM and sonoporation (BS) groups. In another experiment, four experimental groups were composed of the control (C) (n ¼ 4), injection of pVIVO1-mcs and sonoporation (MS) (n ¼ 5), injection of pVIVO1-cdtB (PC) (n ¼ 5) and injection of pVIVO1-cdtB and sonoporation (PS) (n ¼ 5) groups. Ca9-22 cells (1 Â 10 6 in 0.2 ml serum-free DMEM) were subcutaneously injected into the backs of the mice. Tumor size on perpendicular axes was measured daily and tumor volume was calculated by the formula: (Volume (mm )/2). 19 Tumors that had reached an average volume of 55-65 mm 3 at 14 days after transplantation were used in the following experiments. In some experiments, tumor that had reached a volume of 30 mm 3 after transplantation was used for immunoblot analysis as described below.
Mice were anesthetized with an intraperitoneal injection of sodium pentobarbital (60 mg/kg of body weight). The BLM and Optison solution (50 ml; 1:1) or pVIVO1-cdtB and Optison solution (90 ml; 1:3) was directly injected into the tumor region with a 27-gauge needle. The final concentrations of BLM and pVIVO1-cdtB were 0.4 mg/ml and 1.2 mg/ml, respectively. The tumor was covered with an ultrasonication conducting gel, Aloe-Sound Lotion (Rich Mar Inc., Inola, OK) and exposed to ultrasonication twice for 1 min using a Sonitron 2000 at 1 MHz, with an output intensity of 2.0 W/cm 2 and a 50% duty cycle. The temperature at the surface of lesion was monitored with a digital thermistor probe (DFT-600; Shinko Co., Tokyo, Japan). In all cases, the temperature difference before and after sonoporation was less than 21C. All the experiments with mice were carried out with the approval of the Kyushu Dental College Experimental Animal Care and Use Committee.
Histochemical analyses of TdT-mediated dUTP end-labeling (TUNEL)-positive and caspase 3-expressing cells The mice were kept under observation for 4 weeks as described above, then killed for histochemical examinations. The tissues were embedded in paraffin after treatment with 10% formalin in 0.1 M phosphate buffer (pH 7.3). To detect nuclei with DNA fragmentation, a TUNEL-staining method was performed using a Tumor TACS apoptosis detection kit (Trevigen, Inc. Gaithersburg, MD). As members of a family of caspases including caspase-3 have been implicated as mediators of apoptotic cell death, immunostaining of active caspase-3 was performed using the anti-active caspase-3 monoclonal (Promega, Madison, WI) and Alexa Fluor 488 goat antirabbit IgG (H þ L) (Molecular Probe, Inc) antibodies.
Immunoblot analysis
The samples were lysed in a lysis buffer (75 mM Tris-HCl containing 2% SDS and 10% glycerol, pH 6.8). Protein contents were measured using a DC-protein assay kit (Bio-Rad, Hercules, CA). The samples were electrophoresed using 15% sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred to PVDF membranes (Millipore, Bedford, MA). Nonspecific binding sites were blocked by immersing the membranes in 10% skim milk in PBS for 1 h at room temperature, and the membrane was washed four times in PBS, followed by incubation in diluted primary antibody for 2 h at room temperature. The primary antibodies used in this experiment were a polyclonal anti-His-probe (G-18) antibody and anti-Actin (C-2) antibody (Santa Cruz Biotechnology), whereas the secondary antibodies were anti-rabbit and anti-mouse IgG-horseradish peroxidase (HRP; Santa Cruz Biotechnology). After washing of the membrane, chemiluminescence was produced using an enhanced chemiluminiscent (ECL) reagent (Amersham Pharmacia Biotech) and detected with Hyperfilm-ECL (Amersham Pharmacia Biotech, Uppsala, Sweden).
Results

In vitro sonoporation
The delivery of BLM (5 mg/ml) into Ca9-22 cells was performed by sonoporation in the presence of Optison. After sonoporation, the cells were cultured with BLM and Optison for 30 min, then washed with PBS, after which the cells were cultured in DMEM containing 10% fetal bovine serum for 4 days. Treatment with sonoporation strongly inhibited the growth of Ca9-22 cells when Optison was added to the BLM solution. On the other hand, when Optison was not added, scant growth inhibition was observed in Ca9-22 cells treated with sonoporation ( Figure 1) .
We determined the percentage of apoptotic Ca9-22 cells by examining hypodiploid DNA using flow cytometry. When Ca9-22 cells were treated with BLM (5 mg/ml), the percentage of cells with hypodiploid DNA was 17.7% (Figure 2a) . To investigate the nature of Ca9-22 cell death following intracellular delivery of BLM using sonoporation, we analyzed the cells with a combination of Annexin V and PI. Flow cytometric analysis revealed that delivery of BLM by sonoporation enhanced the surface expression of phosphatidylserine after being cultured for 24 and 48 h, as shown by an increase of Annexin V binding ( Figure 2b ). We also examined apoptotic nuclei in BLMdelivered Ca9-22 cells using Hoechst's staining. As shown in Figure 2c , apoptotic cells were identified according to 
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To explore whether in vitro transfection of the pEF1a-b-GAL plasmid leads to expression of b-galactosidase following sonoporation, the number of b-galactosidaseexpressing cells was counted. Although no X-Gal-stained cells were found in the control group, a remarkable number of cells was stained after sonoporation in the presence of Optison (Figure 3a) . Further, transfection efficiency was significantly decreased when the cells were ultrasonicated without Optison (Figure 3b) . Next, we examined whether pVIVO1-cdtB-tranfected Ca9-22 cells underwent apoptosis using Hoechst's staining. No apoptotic Ca9-22 cells were detected following sonoporation with the pVIVO1-mcs control plasmid. On the other hand, some apoptotic cells were detected at 24 h after pVIVO1-cdtB was transfected into Ca9-22 cells by sonoporation in vitro (Figure 4) . No apoptotic Ca9-22 cells were detected following sonoporation with the pVIVO1-cdtB plasmid in the absence of Optison (data not shown).
In vivo sonoporation As delivery of BLM or the pVIVO1-cdtB plasmid by sonoporation in the presence of Optison specifically inhibited the growth of Ca9-22 cells in vitro, we examined the effect of sonoporation on tumor growth in KSN/slc nude mice in vivo. Ca9-22 cells were inoculated into male nude mice and tumor formation (volume nearly 60 mm Next, we examined the effect of pVIVO1-cdtB-transfection into nude mice on tumor growth in vivo. In this experiment, the volume of massive and solid tumors was increased in the Ca9-22 cell-inoculated animal control groups (C, MS and PC), whereas mice transfected with pVIVO1-cdtB by sonoporation in the presence of Optison (PS) showed completely suppressed tumor growth ( Figure  7a and b) . At the end of the experimental period (56 days after initiation of sonoporation therapy), all tumors in the mice had disappeared, whereas the volume of solid tumors was increased and a necrotic region was found (Figures 5a and 7a ). In addition, we found no inhibitory effect on tumor growth when pVIVO1-cdtB was transfected into mice by sonoporation in the absence of Optison (data not shown). As shown in Figure 8 , a large number of TUNEL-positive ( Figure 8a ) and caspase 3-positive ( Figure 8b ) cells were detected in specimens from mice treated by sonoporation in the presence of the pVIVO1-cdtB plasmid and Optison.
Expression of cdtB by in vitro and in vivo sonoporation
To clarify whether the cdtB protein was expressed in Ca9-22 cells by in vitro sonoporation and in tissue of Ca9-22 cell-inoculated mice by in vivo sonoporation, we examined expression level of cdtB by immunoblot analysis. As shown in Figure 9a , the expression of cdtB (32 kDa) was detected in Ca9-22 cells, after the pVIVO1-cdtB plasmid was transfected by sonoporation in the presence of Optison. Next, we examined the effect of in vivo sonoporation on the expression of cdtB in mice tissue. Ca9-22 cells were subcutaneously inoculated into the backs of the mice. The pVIVO1-cdtB plasmid was injected into tumors (30 mm 3 ) with or without Optison. Immunoblot analysis revealed that the expression of cdtB in tumor from mice treated by in vivo sonoporation with the pVIVO1-cdtB plasmid and Optison (Figure 9b ).
Discussion
Oral squamous cell carcinomas are the most common type of malignant neoplasm and are reported to occur on the lips, tongue, floor of the mouth, gingiva, palate, tonsils, buccal mucosa and uvula. An important factor for the success of clinical therapy treatment for squamous cell carcinoma is the state of lymph node metastasis. 20, 21 In the maxilla, squamous cell carcinomas often invade into the maxillary sinus, whereas in the mandible, extension into the floor of the mouth often occurs. Although clinical treatment is generally accomplished with surgery in those cases, the prognosis is not particularly good and the use of antiproliferative agents, such as 5-fluorouracil, mitomycin C and BLM, has been reported to remarkably improve the therapeutic effect. 22 Systemic administration of these drugs results in general toxicity, thus, to avoid unexpected complications, several local drug delivery methods have been rapidly developed. Among them, BLM is administrated as an intravenous or intratumoral injection along with electrochemotherapy. 23 It is well known that the cytotoxicity of BLM is mainly owing to direct DNA damage. 24 BLM has been reported to cut chromatin at the level of the linker DNA between nucleosomes, resulting in single-and double-strand DNA breaks, which are seen as chromosomal gaps, deletions and DNA fragmentation. [25] [26] [27] It has also been shown that a few BLM molecules induce cellcycle arrest in the G2/M phase and then the cells die in a slow process, whereas a relatively high concentration of BLM kills the cells through apoptosis by creating characteristic DNA fragmentation, followed by cell shrinkage, membrane blebbing and chromatin condensation. 28, 24 In addition, a study found that less than 0.1% of the BLM added to extracellular medium becomes extremely toxic for the cells. 29 These findings are in accordance with the present results, in which condensation and degradation of nuclei were detected, after delivery of a low concentration of BML (5 mg/ml) by sonoporation in the presence of Optison and few apoptotic cells were detected with BML (5 mg/ml) alone (Figure 2 ).
In our previous study, we successfully delivered rcdtB derived from the periodontopathic bacterium A. actinomycetemcomitans using a BioPORTER protein delivery reagent, which is a new and efficient reagent for intracellular delivery of bioactive molecules and concluded that the BioPORTER liposomes enhanced the fusion processes to deliver rcdtB into Ca9-22 cells. 15 LaraTejero et al.
12 also demonstrated that cdtB-associated deoxyribonuclease (DNase) activity is responsible for cdt-induced cell cycle arrest and suggested that DNase activity is essential for cdt toxicity. In addition, Mao X and DiRicnzo 30 demonstrated that purified cdtB converted supercoiled plasmid DNA to relaxed and linear forms, which suggested a functional relationship between DNase-related residues in cdtB and cdt biological activities. Our results also indicated that cdtB derived from A. actinomycetemcomitans was sufficient to induce G2 cell cycle arrest of tumor cells. 31 Taken together, these findings strongly suggest that cdtB protein and its gene cdtB could be used in precisely targeted cancer therapy.
Previously, we successfully transfected pVIVO1-cdtB into Ca9-22 cells by lipofection and electroporation and our results indicated that transfection of pVIVO1-cdtB induces apoptosis in human gingival squamous cell carcinoma cells in vitro. 15 In the present study, we confirmed the usefulness of sonoporation for the transfection of pEF1a-b-GAL and pVIVO1-cdtB into Ca9-22 cells in vitro ( Figure 3) . As the pVIVO1-mcs plasmid used in the present study is a unique generation multigenic vector with two transcription units, which allows high levels of expression of cloned transgenes in vitro and in vivo, 32 we used it to examine the efficacy of pVIVO1-cdtB on the induction of apoptosis in Ca9-22 cells transfected by sonoporation. Actually, we confirmed the expression of cdtB in Ca9-22 cells using pVIVO1-cdtB plasmid in in vitro experiment (Figure 9a ). Hoechst's staining revealed that transfection of pVIVO1-cdtB induced apoptosis in human gingival squamous cell carcinoma cells in vitro (Figure 4) . Thereafter, our attention focused on the effect of the cdtB gene on the viability of Ca9-22 cells in vivo.
It is well known that sonoporation induces cell membrane porosity and enhances the delivery of naked DNA into cells in vitro 33 and in vivo. 5 Recently, the method of ultrasound induction of membrane permeabilization and resealing has been termed sonoporation. 34, 35 Previous findings on the enhanced effect of sonoporation provided by microbubble echo-contrast agents led us to investigate its therapeutic efficacy with BML and cdtB-expressing plasmid DNA in vivo.
It has been shown that when administrated as an intratumoral injection, BLM dosage is usually dependent on tumor volume. 36, 37 In addition, as oral squamous cell carcinomas frequently occur on the lips, tongue, gingiva, palate, tonsils and buccal mucosa, that type of injection is convenient. In the present study, we found that BLM (20 mg) treatment with sonoporation in the presence of Optison significantly inhibited tumor growth, as compared with the control groups ( Figure 5) . Further, histological analysis revealed that the cytotoxic effect was mainly apoptosis. The concentration of BLM in the present study was consistent with previous results showing that electroporation-mediated delivery of BLM induces marked suppression of treated tumors. 19, 38 In our preliminary experiments, we confirmed the optimal conditions in regard to output intensity and duty cycle to obtain a high level of toxicity and expression of cdtB in vivo (data not shown).
Several studies have described the clinical usefulness of sonoporation for intracellular delivery of bioactive molecules, such as proteins, antibodies and plasmids, into mammalian cells. 1, 6, 7 Focused sonoporation is a novel technique for cancer therapy that has received attention, as sonoporation makes the cell membrane permeable to macromolecules that are normally nonpermeating, such as BLM and cdtB used in the present study and large amounts of these molecules can enter cells and directly damage the DNA. Recently, Tachibana et al. 39 developed DNA-carrying microbubbles that function as an ultrasound contrast agent. It has also been reported that gasbody-based contrast agents, such as Optison and BR14, enhance the nonthermal effects of sonoporation toward gene transfer 5, 40, 41 and some studies have used these microbubbles to increase gene transfection. Among the commercially available echo-enhanced contrast agents, including Optison, Alubunex,and Levovist, the former was shown to be more effective in increasing the rate of gene transfection in vitro and in vivo. 39 Optison consists of gas-filled microspheres surrounded by a solid shell of heat-denatured human albumin, which is widely used in clinical therapy. 42 It has been reported that the transfection efficiency of plasmid DNA is increased using echocontrast agents. 43 Ultrasound exposure in the presence of a photosensitive drug was found to induce a very rapid process of cell membrane porosity during sonication. 33 These findings are consistent with our results that showed remarkable numbers of b-galactosidase-expressing cells and enhanced-cdtB expression level after sonoporation in the presence of Optison (Figures 3a and 9) .
In the present study, we established in vitro delivery and in vivo transfection systems for BLM and the cdtB gene into oral squamous cell carcinomas using sonoporation. Our results showed that gingival squamous cell carcinoma cells underwent apoptosis following delivery of those molecules. Further, we clarified that in vivo sonoporationmediated transfer of low-dose BLM and the cdtB gene induced a significant therapeutic effect on human gingival squamous cell carcinomas in a mouse experimental model. These findings suggest possible application of focused sonoporation for chemotherapy and gene therapy as treatment for solid squamous cell carcinoma.
